NRx Pharmaceuticals Announces the Licensure of a US Patent to Support Use of NRX-101™ for Chronic Pain

Posted on by

NRx has Licensed US Patent 8,653,120 for use of D-Cycloserine to treat Chronic Pain Dr. Vania Apkarian, a world leader in pain and D-Cycloserine (DCS) research, has joined the NRx Scientific Advisory Board RADNOR, Pa., Aug. 7, 2023 /PRNewswire/ — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.